Helping Children Receive an Earlier Autism Diagnosis

For Parents For Providers

Earlier Diagnosis + Earlier Intervention = Better Outcomes

Click here to read our newest publlication in Autism Research

The NPDX ASD blood test is a new diagnostic tool that may lead to an earlier diagnosis for children with autism spectrum disorder (ASD).

About Our Autism Blood Test

Our blood test is validated by our National Institutes of Mental Health clinical study, the largest study to evaluate the metabolism of children with autism.

How Our Test Was Validated

The results of our clinical study were published in the scientific journal, Biological Psychiatry.

The Science Behind Our Test

We improve the lives of children and families living with autism spectrum disorder by providing tools for earlier diagnosis and more precise treatment.

Our Mission and Leadership

Earlier access to specialty care and treatments improve outcomes

Talk to your healthcare Provider (pediatrician, family doctor) about requesting our test for your child.

Talking to Your Provider

Print the NeuroPointDX brochure which summarizes our company and our autism test for your Provider.

The NPDX ASD Brochure

Sign-up to receive updates on our progress developing tools for autism diagnosis and treatment.

Sign-Up for Newsletters

Publications

NeuroPointDX, through its parent company Stemina Biomarker Discovery, has published papers in peer-reviewed journals and presented research at meetings around the world.

Unique Metabolic Signatures Associated with Autism Spectrum Disorder (ASD) Detect More than 50% of individuals with ASD in Children’s Autism Metabolome Project (CAMP)

MADISON, Wisc.--(BUSINESS WIRE)-- In a paper published online this week in Autism Research, scientists at NeuroPointDX, a division of Stemina Biomarker Discovery, Inc., in collaboration with researchers at the UC Davis MIND Institute and academic and clinical institutions across the country, report new findings from the Children’s Autism Metabolome Project or CAMP. Analysis of blood samples from CAMP, the largest[...]

Posters

NeuroPointDX, through its parent company Stemina Biomarker Discovery, has published papers in peer-reviewed journals and presented research at meetings around the world.

Identification of Neurotransmitter-Associated and Other Metabotypes: Further Stratification of the Children’s Autism Metabolome Project (CAMP) ASD Subjects

Presented at the 2019 Annual Meeting of the International Society for Autism Research (INSAR) in Montreal, Ontario, Canada in May 2019. The Children’s Autism Metabolome Project (CAMP), ClinicalTrials.gov: NCT02548442, recruited 1,100 children for metabolomic analyses to identify altered metabolism associated with ASD. Previous research identified ASD subjects associated with branched-chain amino acid (BCAA) dysregulation. With this[…]

Unique Metabolic Signatures Associated with Autism Spectrum Disorder (ASD) Detect More than 50% of individuals with ASD in Children’s Autism Metabolome Project (CAMP)